Mobia Medical (NASDAQ:MOBI – Get Free Report) was upgraded by equities researchers at The Goldman Sachs Group to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.
Several other equities research analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Mobia Medical to a “hold” rating in a report on Saturday, May 16th. Bank of America initiated coverage on shares of Mobia Medical in a report on Tuesday. They issued a “buy” rating and a $16.00 target price on the stock. BTIG Research initiated coverage on shares of Mobia Medical in a report on Tuesday. They issued a “buy” rating and a $19.00 target price on the stock. Wolfe Research initiated coverage on shares of Mobia Medical in a report on Tuesday. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. initiated coverage on shares of Mobia Medical in a report on Tuesday. They issued an “overweight” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. According to MarketBeat.com, Mobia Medical presently has a consensus rating of “Buy” and a consensus price target of $20.25.
View Our Latest Research Report on Mobia Medical
Mobia Medical Trading Down 0.4%
Insider Buying and Selling
In other Mobia Medical news, Director Cynthia L. Lucchese acquired 125,000 shares of the stock in a transaction dated Monday, May 11th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $1,875,000.00. Following the completion of the acquisition, the director directly owned 125,000 shares of the company’s stock, valued at approximately $1,875,000. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dana G. Jr. Mead bought 7,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $15.00 per share, with a total value of $105,000.00. Following the transaction, the director owned 7,000 shares of the company’s stock, valued at $105,000. This represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 1,268,332 shares of company stock valued at $19,024,980 over the last ninety days.
See Also
- Five stocks we like better than Mobia Medical
- As AI Data Breaches Become More Common, This Cybersecurity ETF Is SurgingAI
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
Receive News & Ratings for Mobia Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mobia Medical and related companies with MarketBeat.com's FREE daily email newsletter.
